That’s usually where the discussion begins.Safety reviewers pull the data again. Signal Management Pharmacovigilance, They re-check narratives. They look at timelines. Is there a pattern? Is it clinically meaningful? Could there be confounding factors? These conversations don’t always lead to confirmed risks, but they matter. Because occasionally, one of those discussions turns into a genuine safety finding.